Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
- First Online:
- Cite this article as:
- Scott, L.J., Yang, L.P.H. & Lyseng-Williamson, K.A. Drugs Aging (2012) 29: 243. doi:10.2165/11209160-000000000-00000
- 157 Downloads
Oral abiraterone acetate (Zytiga®), a selective cytochrome P450 17A1 enzyme inhibitor, is used in combination with prednisone or prednisolone to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. In a clinical trial in patients with CRPC, abiraterone acetate plus prednisone significantly prolonged overall survival, the time to prostate-specific antigen progression and progression-free survival compared with placebo plus prednisone.